The biopharmaceutical company pledges to drive increased awareness around rare diseases in India through its Indian entity.
India is grappling with the challenges posed by rare diseases. The absence of a rare disease policy, low disease awareness amongst patients and lack of accessibility to specialists are critical factors that make the rare disease patients furthermore vulnerable.
In India, more than 70-100 million people are suffering from rare diseases, of which treatment options are available for 450 conditions. Furthermore, rare diseases disproportionately impact children: 50% of new cases are in children and are responsible for 35% of deaths before the age of 1 year.
The most common rare diseases identified in India are Haemophilia, Thalassemia, Sickle-cell Anaemia, Primary Immuno Deficiency, Lysosomal Storage Disorders such as Gaucher Disease, Fabry Disease, Hunter Syndrome and Pompe’s Disease.
To celebrate Rare Diseases Day, Takeda, a global, values-based, R&D-driven biopharmaceutical company pledges to drive increased awareness around rare diseases in India through its Indian entity. The company is committed to support faster diagnosis and better access to treatments for patients with rare diseases.
Speaking on the occasion of Rare Disease Day, Vineet Singhal, General Manager and Country Head, Takeda India, said “As a company, we are committed to serve patients suffering from rare diseases like Hunter’s syndrome, Gaucher and Fabry and support them in their disease journey to ensure improved quality of life. We intend to leverage and replicate curated initiatives and global best practices in India for the benefit of the patients.”
As part of International Rare Disease Day, Takeda globally has launched “Constellation of Rare Stars” to honour patients, families, caregivers, health care professionals and community members who have helped to “Reframe Rare.”